 |
No vials, no needles, no reconstitution
 RotaTeq is for oral use only. Not for injection. RotaTeq: New packaging
Click to see a demonstration of how to open the new packaging.
Use with other vaccines
In clinical trials, RotaTeq was
routinely administered concomitantly with diphtheria
and tetanus toxoids and
acellular pertussis (DTaP), inactivated poliovirus
vaccine (IPV), H. influenzae type b conjugate vaccine (Hib),
hepatitis B vaccine, and pneumococcal conjugate vaccine.
There was no evidence for reduced antibody responses
to the vaccines that were concomitantly administered
with RotaTeq.
- RotaTeq is indicated for the prevention
of rotavirus gastroenteritis in infants and children
caused by the serotypes G1, G2, G3, and G4 when administered
as a 3-dose series to infants between the ages of 6 to
32 weeks.
- The vaccination series consists of 3 ready-to-use liquid
doses of RotaTeq administered orally starting at 6 to 12 weeks of age,
with the subsequent doses administered at 4- to 10-week intervals. The
third dose should not be given after 32 weeks of age.
Select safety information
- RotaTeq should not be administered
to infants with a demonstrated history of hypersensitivity
to the vaccine or any component
of the vaccine.
- No safety or efficacy data are available
for the administration of RotaTeq to infants who are potentially
immunocompromised
or to infants with a history
of
gastrointestinal disorders.
- Caution is advised when considering whether
to administer RotaTeq to individuals with immunodeficient
contacts.
- In clinical trials, the most common adverse events
included diarrhea, vomiting, irritability, otitis media,
nasopharyngitis, and bronchospasm.
- In post-marketing experience,
intussusception (including death) and Kawasaki disease
have been reported in infants who
have received RotaTeq.
- RotaTeq may not protect all vaccine
recipients against rotavirus.
Before administering RotaTeq, please read the Prescribing
Information
and Patient
Product Information.
RotaTeq is a registered trademark of Merck & Co.,
Inc.
|
